AnaptysBio saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 70 to 73.
Can You Really Time The Stock Market?
This unique rating measures technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the best stocks tend to have an 80 or better RS Rating as they launch their largest price moves. See if AnaptysBio can continue to show renewed price strength and clear that threshold.
AnaptysBio is not currently near a potential buy zone. See if the stock goes on to form a sound pattern that could kick off a new price move.
The company reported 0% earnings growth last quarter, while sales growth came in at 287%. The next quarterly results are expected on or around Aug. 11.
AnaptysBio earns the No. 139 rank among its peers in the Medical-Biomed/Biotech industry group. Incyte, Halozyme Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
